Exexcutive spotlight

sponsored by

Expert panel

What blood cancer data made headlines at ASH? Join researchers and industry leaders to break down the top readouts.

sponsored by

Taking on field leaders with Arcellx and Gilead

Arcellx is heading to ASH with new data on its multiple myeloma cell therapy, which it is developing with Gilead’s cell therapy subsidiary, Kite. We’ll sit down with Arcellx CEO Rami Elghandour and Executive Vice President of Kite Cindy Paretti to talk about the readout and why they think the drug can take on Carvykti.

sponsored by

Advancing polycythemia vera care: Challenges, innovations & future directions

Join top clinicians and individuals living with PV to discuss unmet needs, current management, and the evolving treatment landscape. The conversation will cover challenges with hematocrit control, symptom burden, and limitations of today’s therapies, along with emerging options in development including hepcidin mimetics and siRNA-based approaches. Patient panelists will share real-world experiences that highlight where innovation is most needed.

sponsored by